[Seroprevalence of measles antibody and its attributable factors in elementary students of routine 2-dose schedule era with vaccination record].
OBJECTIVE
We investigated the seroprevalence of the measles antibody and its attributable factors for the students who underwent routine 2-dose Schedule Era.


METHODS
The subjects were 996 students of the national measles seroepidemiologic study in December 2000 who had vaccination records. We conducted a questionnaire survey and we performed serologic testing for the measles-specific IgG by using an enzyme linked immunosorbent assay.


RESULTS
The coverage for the first dose of the MMR vaccination at 12-15 months of age was 95.1% and the coverage for the second dose of MMR at 4-6 years of age was 35.0%. The proportion of subjects undergoing 2-doses of MMR decreased as the age of the subjects increased. The seropositive rate of the measles antibody was significantly high in the second dose vaccinees (93.5% in the second dose group, 84.7% in the non-second dose group, p<0.001) and it was 72.0% in the 0-dose group, 85.4% in the 1-dose group and 93.7% in the 2-dose group (p<0.001). Two point eight percent of the subjects had a past history of measles infection. On the multiple logistic regression analysis, the first and second dose (odds ratio, 8.54; 95% CI.=3.05-23.91), the first dose (odds ratio, 3.06; 95% CI.=1.20-7.81) and the outbreak in the year 2000 (odds ratio, 1.89; 95% CI.=1.24-2.88) were the significant factors for the seropositivity.


CONCLUSIONS
Maintaining high coverage with a 2-dose vaccination program would be the decisive factor to prevent an outbreak of measles and to eliminate measles in Korea.
Bae
Geun-Ryang
GR
Department of Preventive Medicine, College of Medicine, Dongguk University. bgr824@dongguk.ac.kr
Lim
Hyun-Sul
HS
Goh
Un-Yeong
UY
Yang
Byung-Guk
BG
Kim
Young-Taek
YT
Lee
Jong-Koo
JK
D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006306:Health Surveys; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data*; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007723:Korea; D008297:Male; D008457:Measles / Q000276:immunology / Q000517:prevention & control*; D008459:Measles virus / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D012574:Schools; D016036:Seroepidemiologic Studies; D013334:Students; D011795:Surveys and Questionnaires
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D022542:Measles-Mumps-Rubella Vaccine